1. Scrip
  2. >>Drug Pricing

UK Experimental AMR Payment Program “On Track”

Two Antibiotics To Be Identified For Assessment By Year-End

 
• By Sten Stovall

Designers of the UK’s experimental antibiotic payment system aim to identify two drugs later this year which will then undergo a novel technology assessment in 2021.

Incentives_Magnet
UK trials world's first ‘subscription’ payment model for novel antibiotics • Source: Shutterstock

Health authorities in the UK remain on track with their program for testing a "pull" reward incentive mechanism as a way to both ensure adequate supply of antibiotics - a drug class that is fast ebbing away – while stimulating innovation for new antimicrobial drugs, a process that will also use health technology evaluations of the added value from any new antimicrobial, one of the project’s team leaders told Scrip.

The AMR ‘develop and test’ program, which first launched last summer, seeks to find a balance between supply and demand that reflects the fact that antibiotics tend to be for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.